Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Promising FA Treatment | Larimar's nomlabofusp shows potential as a groundbreaking therapy for Friedreich's ataxia, with clinical trials expanding to include younger patients |
Financial Runway | Strong $226M cash position funds operations into 2026, but high R&D expenses and net losses pose challenges to long-term stability |
Regulatory Milestones | Explore Larimar's path to BLA submission, with potential accelerated approval based on frataxin level increases and crucial data releases expected |
Market Dynamics | Analysts set price targets ranging from $21 to $25, as Larimar navigates competition from approved treatments and pipeline candidates in the FA market |
Metrics to compare | LRMR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLRMRPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.3x | −3.2x | −0.5x | |
PEG Ratio | 0.06 | −0.01 | 0.00 | |
Price/Book | 2.2x | 2.6x | 2.6x | |
Price / LTM Sales | - | 8.7x | 3.3x | |
Upside (Analyst Target) | - | 180.1% | 40.3% | |
Fair Value Upside | Unlock | 5.3% | 4.7% | Unlock |